The purpose of the SQL/LSA Clinical Research Program is to aid in the development of new therapies and assays, enhance patient care, and improve clinical outcomes. 

Active collaboration with diagnostic, biotechnology, and pharmaceutical companies, academic institutions, health care systems, and governmental agencies is essential as it builds healthier communities.

Our program provides clinical and technical support for the following project/study types:

  • Material Transfer

  • Scholarly Projects

  • Clinical Trials

  • Data Analytics

  • Purchased Laboratory Services


Non-disclosure Agreement (NDA)

If you require a Non-disclosure Agreement (NDA) prior to requesting research support, please utilize the SQL/LSA Non-disclosure Agreement Template. Upon completion, submit the document to the email address provided within the NDA.

Basic Evaluation Process: 
Initial Feasibility Intake Review Form

 

Frequently Asked Questions (FAQs)

How long does it typically take for the SQL/LSA Research Committee to review the Initial Feasibility Intake Review Form?

The SQL/LSA Research Committee usually provides a response within 2 weeks from the submission date. The submitter will be notified if the study/project is accepted or rejected.

Once I receive approval from the SQL/LSA Research Committee can I start my research study?

No, the purpose of the Initial Feasibility Review Form is to determine if the SQL/LSA clinical laboratory can accommodate your study requirements. This pre-screening piece is required when submitting a study or project to your organizations research committee.

If there are changes to my study following approval will I need to resubmit my study to the SQL/LSA Research Committee?

Under most circumstances the answer is no. If the changes in your study require a significant increase in the demands on the laboratory it may require resubmission. If your study has changed, send an email to the Clinical Research Program Manager outlining the changes and we will provide further instructions.

Does SQL/LSA Research provide assistance with IRB and/or study budget document preparation?

Yes. The fees for these services are determined by the scope and complexity of each study project. Please contact the Clinical Research Program Manager named on this website for more information.

Is there a fee associated with Banner Health Laboratory/Pathology (managed through Laboratory Sciences of Arizona) or Sonora Quest Laboratories’ research related laboratory services?

Yes. The fees for research related laboratory services may include, but are not limited to: expendables, labor, shipping and storage. A price quote can be prepared upon request. The final fees will be set forth in the applicable research related agreement. 

What are the 18 identifiers under HIPAA?

APPENDIX 1

HIPAA Privacy Rule Standard for De-Identification – Removal of 18 Identifiers

See 45 CFR 164.514(b) for detailed description of identifiers and exceptions

A

Names

J

Account numbers
B Geographic Subdivisions smaller than State (street address, city, county, precinct, ZIP code) K Certificate/license numbers
C Dates (all elements, including birth date, admission date, discharge date, death date, all ages over 89) L Vehicle identifiers and serial numbers, including license plate numbers
D Telephone numbers M Device identifiers and serial numbers
E Fax numbers N Web Universal Resource Locators (URLs)
F Email addresses O Internet Protocol (IP) addresses
G Social security numbers P Biometric identifiers, including finger and voice prints
H Medical record numbers Q Full-face photographs and any comparable images
I Health plan beneficiary numbers R Any other unique identifying number, characteristic, or code, except as permitted by paragraph C below


(c) Implementation specifications: re-identification. A covered entity may assign a code or other means of record identification to allow information de-identified under this section to be re-identified by the covered entity, provided that:

(1) Derivation. The code or other means of record identification is not derived from or related to information about the individual and is not otherwise capable of being translated so as to identify the individual; and 

(2) Security. The covered entity does not use or disclose the code or other means of record identification for any other purpose, and does not disclose the mechanism